Exelixis Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Exelixis Inc in the second quarter 2026?
Exelixis Inc achieved a return on average equity (ROE) of 93.62 % in its second quarter 2026, this is above EXEL's average return on equity of -12.52%.
Exelixis Inc s equity during the 12 months ending in the second quarter 2026 are valued at $2 billion

While the company's net income was fading, Exelixis Inc was able to improve its ROE compared to the first quarter 2026.

Within the Biotechnology & Pharmaceuticals industry 2 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 97 to 114.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jul 03 2026) II. Quarter	(Apr 03 2026) I. Quarter	(Jan 02 2026) IV. Quarter	(Oct 03 2025) III. Quarter	(Jul 04 2025) II. Quarter
Y / Y Equity Change	-9.33 %	-9.16 %	-3.69 %	-5.04 %	-
Y / Y Net Income Change	14.32 %	30.89 %	53.16 %	63.53 %	-19.98 %
Net Income (TTM) in Millions	1,896	1,837	1,724	1,551	1,378
Return On Equity (TTM)	93.62 %	88.6 %	81.25 %	72.41 %	63.47 %
EXEL's Total Ranking	# 114	# 97	# 78	# 87	# 10
Equity (TTM) in Millions	1,844	1,936	2,161	2,161	2,034
Seq. Equity Change	-4.75 %	-10.44 %	0.03 %	6.25 %	-4.57 %
Seq. Net Income Change	-0.72 %	-3.83 %	11.49 %	7.4 %	13.68 %

Back to EXEL Management Effectiveness >> EXEL's 5 Years Annual ROE >> Compare EXEL ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 3
Sector	# 18
Overall	# 114

Return On Equity Statistics
High	Average	Low
213.66 %	-12.52 %	-1364.84 %
(Mar 30 2012)		(Sep 30 2014)

News about Exelixis Inc Return on Equity ROE

Exelixis Navigating the Landscape of Innovation and Litigation

In a series of significant updates, Exelixis, Inc. has made waves in the biopharmaceutical landscape through a combination of legal victories, clinical collaborations, and promising clinical trial results. As the company continues to build on its cancer treatment portfolio, the implications of these developments could profoundly shape its future. Patent Litigation SuccessExelixis recently secured a critical victory in the ongoing patent litigation against MSN Laboratories. The U.S. District Court for the District of Delaware ruled in favor of Exelixis, upholding the validity of three key patents associated with its drug cabozantinib: U.S. Patents No. 11,091,439, 11,091,440, and 11,098,015. These patents are critical as they cover essential aspects of cabozantinib, including a crystalline salt and pharmaceutical compositions. The court s decision not only strengthens Exelixis s intellectual property rights but also safeguards its revenue potential. By reinforcing its patent protections, Exelixis can maintain its market exclusivity for cabozantinib, thereby mitigating the risk of generic competition that could lead to significant revenue loss. This outcome is vital for maintaining investor confidence and continuing to fund research and development initiatives.

EXEL Annual Return On Equity	(Jan 02 2026) 2025	(Jan 03 2025) 2024	(Dec 29 2023) 2023	(Dec 30 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	2,161	2,244	2,264	2,488	2,211
Y / Y Equity Change	-3.69 %	-0.87 %	-9.02 %	12.57 %	17.64 %
Net Income in Millions	1,724	1,203	465	417	525
Y / Y Net Income Change	43.3 %	158.53 %	11.68 %	-20.67 %	369.86 %
Return On Equity	79.76 %	53.6 %	20.55 %	16.74 %	23.76 %

Back to EXEL Management Effectiveness >> EXEL's 5 Years Annual ROE >> Compare EXEL ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 79.76 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
EXEL's' Return on Equity at Yahoo Finance
EXEL's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for EXEL's Competitors
Subscribers only: Roe for Exelixis Inc 's Suppliers
Subscribers only: Return On Equity for EXEL's Customers

Companies with similar Return On Equity at Jul 03 2026, within Healthcare Sector	ROE
Actinium Pharmaceuticals Inc	213.46 %
Halozyme Therapeutics Inc	180.63 %
Capforce Inc	168.50 %
Aveanna Healthcare Holdings Inc	150.35 %
Liquidia Corporation	149.64 %
Interpace Biosciences Inc	142.98 %
Oncotelic Therapeutics Inc	124.17 %
Fortress Biotech Inc	118.22 %
Medpace Holdings Inc	110.15 %
Pulmatrix Inc	108.83 %
Arbutus Biopharma Corp	106.04 %
Rigel Pharmaceuticals Inc	96.49 %
Exelixis Inc	93.62 %
Alnylam Pharmaceuticals Inc	93.61 %
Eli Lilly And Company	92.54 %
Amgen Inc	89.32 %
Q32 Bio Inc	76.88 %
3m Company	76.55 %
Oramed Pharmaceuticals Inc	73.03 %
Tg Therapeutics Inc	72.30 %
Idexx Laboratories Inc	71.96 %
Elite Pharmaceuticals Inc	71.10 %
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %

Date modified: 2026-09-13T23:29:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.